S&P Healthcare Services SPDR (XHS)

HCA Healthcare has significantly outperformed the broader market this year, and Wall Street analysts are bullish about the stock’s prospects.

Despite Universal Health Services’ outperformance relative to the broader market over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

As Quest Diagnostics underperformed relative to the S&P 500 Index over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Despite Humana underperforming the broader market over the past year, Wall Street analysts remain moderately bullish on the stock’s prospects.

As Henry Schein underperformed the broader market over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

DaVita has surpassed the broader market over the past year, and Wall Street analysts are cautious about the stock’s prospects.

Cardinal Health has underperformed the broader market over the past year, but Wall Street analysts are moderately bullish about the stock’s prospects.

DaVita is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit increase.

Universal Health Services is all set to announce its second-quarter results this month, and Wall Street analysts predict a solid double-digit earnings growth.

As Quest Diagnostics gears up to unveil its second-quarter earnings results, Wall Street analysts remain cautiously optimistic about the stock’s prospects.